You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):就腫瘤相關靶點-唾液酸酶雙功能融合蛋白與Palleon訂立的合作及許可協議
格隆匯 06-28 18:43

格隆匯6月28日丨復宏漢霖(02696.HK)宣佈,公司已於2022年6月28日與Palleon訂立一份合作及許可協議,據此,Palleon與公司同意基於各自專有技術和專利,就(i)Palleon的產品雙功能HER2-唾液酸酶融合蛋白,及(ii)待合作雙方共同開發的另一個腫瘤相關靶點-唾液酸酶雙功能融合蛋白("合作開發產品",與雙功能HER2-唾液酸酶融合蛋白統稱"許可產品")用於人類疾病治療的全球合作開發及於各自許可區域內的生產及商業化作出約定。

據悉,雙功能HER2-唾液酸酶融合蛋白是Palleon自主研發的靶向HER2的抗體-唾液酸酶融合蛋白,作為Palleon最先進的雙功能唾液酸酶之一,雙功能HER2-唾液酸酶融合蛋白已經顯示出治療具有適度至高水平的腫瘤表面唾液聚糖的HER2低表達和HER2高表達的腫瘤的潛力,並且雙功能HER2-唾液酸酶融合蛋白即將進入臨牀試驗支持性研究。

另一個腫瘤相關靶點-唾液酸酶雙功能融合蛋白是將由公司與Palleon共同合作開發的創新型免疫治療產品,擬結合公司已擁有的成熟靶點和Palleon自有的EAGLE技術平台以及唾液酸聚糖在多種腫瘤中高度表達的特性,進一步挖掘腫瘤相關靶點唾液酸酶雙功能融合蛋白的治療潛力。

公吿稱,許可產品為抗體唾液酸酶雙功能融合蛋白,目前在腫瘤治療領域尚無同類產品,有望為患有以免疫系統功能障礙為特徵疾病的患者提供新的治療選擇,具有可觀的市場潛力。此次合作有望基於合作雙方現有的研發技術,共同推進許可產品的研發,進一步豐富公司產品管線,進而增強公司在腫瘤治療領域的綜合市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account